Search results for " vascular endothelial growth factor a"

showing 10 items of 18 documents

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

2017

Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs and…

0301 basic medicineMAPK/ERK pathwayVascular Endothelial Growth Factor AAngiogenesisDrug Evaluation PreclinicalTyrosine kinase inhibitorAngiogenesis InhibitorsReviewFibroblast growth factorCatalysiMetastasisAntineoplastic Agentlcsh:Chemistrychemistry.chemical_compoundangiogenesis0302 clinical medicinetyrosine kinase inhibitorsMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyClinical Trials as TopicMonoclonal antibodieNeovascularization Pathologicvascular endothelial growth factorComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorGene Expression Regulation NeoplasticAngiogenesiChemistryBiliary Tract NeoplasmsTreatment OutcomeBiliary Tract Neoplasm030220 oncology & carcinogenesismonoclonal antibodiesTyrosine kinaseAngiogenesis InhibitorHumanSignal TransductionProtein Kinase InhibitorAntineoplastic Agentsbiliary tract cancersBiologyModels BiologicalAngiogenesis; Biliary tract cancers; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Drug Evaluation Preclinical; Gene Expression Regulation Neoplastic; Genetic Variation; Humans; Models Biological; Neovascularization Pathologic; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A; Molecular Targeted Therapy; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisInorganic Chemistry03 medical and health sciencesIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryGallbladder cancerMolecular BiologyProtein Kinase InhibitorsBiologyAnimalOrganic ChemistryGenetic Variationmedicine.disease030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Immunologyangiogenesis; biliary tract cancers; monoclonal antibodies; tyrosine kinase inhibitors; vascular endothelial growth factorCancer researchBiliary tract cancerInternational Journal of Molecular Sciences
researchProduct

Plasma leptin and vascular endothelial growth factor (VEGF) in normal subjects at high altitude (5050 m)

2013

Context: High altitude (HA) is a model of severe hypoxia exposure in humans. We hypothesized that nocturnal hypoxemia or acute maximal exercise at HA might affect plasma leptin and VEGF levels. Objectives: Plasma leptin, VEGF and other metabolic variables were studied after nocturnal pulse oximetry and after maximal exercise in healthy lowlanders on the 3rd-4th day of stay in Lobuche (5050 m, HA) and after return to sea level (SL). Results: Leptin was similar at SL or HA in both pre- and post-exercise conditions. Pre-exercise VEGF at HA was lower, and cortisol was higher, than at SL, suggesting that nocturnal intermittent hypoxia associated with periodic breathing at HA might affect these v…

AdultLeptinMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyperiodic breathingPhysiologySettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyNocturnalSettore BIO/09 - FisiologiaNOHypoxemiachemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumanssleepExercisemaximal exercise testhypoxiaAltitudeHypoxia maximal exercise test metabolism periodic breathing sleepLeptinHypoxia; Maximal exercise test; Metabolism; Periodic breathing; Sleep; Adult; Exercise; Female; Humans; Hypoxia; Leptin; Male; Oxyhemoglobins; Vascular Endothelial Growth Factor A; Altitude; Healthy Volunteers; Physiology; Physiology (medical)hypoxia; maximal exercise test; sleep; periodic breathing; metabolismIntermittent hypoxiaGeneral MedicineHypoxia (medical)Effects of high altitude on humansHealthy VolunteersVascular endothelial growth factorEndocrinologychemistryOxyhemoglobinsPeriodic breathingFemalemedicine.symptommetabolismArchives of Physiology and Biochemistry
researchProduct

Vascular endothelial growth factor gene polymorphisms in Behçet's disease

2004

Objective. To evaluate potential associations of vascular endothelial growth factor (VEGF) gene polymorphisms with Behçet's disease (BD) and disease expression. Methods. Case patients were 122 consecutive Italian patients with BD followed at the Rheumatology, Ophthalmology, and Neurology Units in Bologna, Ferrara, Milano, Palermo, Potenza, Prato, Reggio Emilia, and Trento over a 3-year period (1997-99) and who satisfied the International Study Group criteria for BD. Also selected as a control group were 200 healthy age and sex matched blood donors. All patients with BD and controls were genotyped by polymerase chain reaction and allele-specific oligonucleotide techniques for +936 C/T (rs302…

AdultMaleVascular Endothelial Growth Factor Aclinical manifestationsPolymorphism GeneticAdolescentGenotypeBehcet SyndromeVEGF productionBehcet's diseaseVEGF polymorphismGene FrequencyLeukocytes MononuclearHumansAdolescent; Adult; Behcet Syndrome; Cells Cultured; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leukocytes Mononuclear; Male; Vascular Endothelial Growth Factor A; Polymorphism GeneticFemaleGenetic Predisposition to DiseaseCells Cultured
researchProduct

Development and Aging Are Oxygen-Dependent and Correlate with VEGF and NOS along Life Span

2012

During development and aging, vascular remodeling represents a critical adaptive response to modifications in oxygen supply to tissues. Hypoxia inducible factor (HIF) has a crucial role and is modulated by oxygen levels, with an age-dependent response in neonates, adult, and aged people. ROS are generated under hypoxic conditions and the accumulation of free radicals during life reduces the ability of tissues to their removal. In this immunohistochemical study we investigated the presence and localization of VEGF and iNOS in human carotid bodies (CB) sampled at autopsy from three children (mean age – 2 years), four adult young subjects (mean age – 44.3 years), and four old subjects (mean ag…

AdultVascular Endothelial Growth Factor AAgingmedicine.medical_specialtyNitric Oxide Synthase Type IIAutopsyBiologyHypoxemiaNitric oxideYoung Adultchemistry.chemical_compoundAnoxiaInternal medicinemedicineHumansYoung adultChildPreschoolAgedCarotid BodyAdult; Aged; Aging; Anoxia; Carotid Body; Cell Differentiation; Child Preschool; Humans; Nitric Oxide Synthase Type II; Oxygen; Vascular Endothelial Growth Factor A; Young AdultCell DifferentiationHypoxia (medical)Oxygenmedicine.anatomical_structureEndocrinologyHypoxia-inducible factorschemistryImmunohistochemistryCarotid bodymedicine.symptom
researchProduct

Arterial hypertension in cancer: The elephant in the room

2019

The great therapeutical success achieved by oncology is counterbalanced by growing evidences of cardiovascular (CV) toxicity due to many antineoplastic treatments. Cardiac adverse events may cause premature discontinuation of effective oncologic treatments or occur as late events undermining the oncologic success. Arterial hypertension is both the most common comorbidity in cancer patients and a frequent adverse effect of anticancer therapies. A pre-existing hypertension is known to increase the risk of other cardiac adverse events due to oncologic treatments, in particular heart failure. Moreover, as a strict association between cancer and CV diseases has emerged over the recent years, var…

Arterial hypertensionVascular Endothelial Growth Factor AAnthracyclines Anti VEGF agents Anti-hypertensive therapy Arterial hypertension Cancer Cardiotoxicitymedicine.medical_specialtyAnti VEGF agentmedicine.medical_treatmentAntineoplastic AgentsBlood PressureAnthracycline030204 cardiovascular system & hematologyAnthracyclines; Anti VEGF agents; Anti-hypertensive therapy; Arterial hypertension; Cancer; Cardiotoxicity; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Humans; Hypertension; Neoplasms; Vascular Endothelial Growth Factor A03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansAnthracyclines030212 general & internal medicineAnti-hypertensive therapyAdverse effectIntensive care medicineAntihypertensive AgentsCancerChemotherapyCardiotoxicitybusiness.industryAnti VEGF agentsCancermedicine.diseaseComorbidityCardiotoxicityDiscontinuationBlood pressureHeart failureHypertensionCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology

2015

Bone morphogenetic proteins (BMPs), members of the TGF-β superfamily, have numerous biological activities including control of growth, differentiation, and vascular development. Using an in vitro co-culture endothelial cord formation assay, we investigated the role of a BMP7 variant (BMP7v) in VEGF, bFGF, and tumor-driven angiogenesis. BMP7v treatment led to disruption of neo-endothelial cord formation and regression of existing VEGF and bFGF cords in vitro. Using a series of tumor cell models capable of driving angiogenesis in vitro, BMP7v treatment completely blocked cord formation. Pre-treatment of endothelial cells with BMP7v significantly reduced their cord forming ability, indicating …

Genetics and Molecular Biology (all)MaleVascular Endothelial Growth Factor AFibroblast Growth FactorAngiogenesisBone Morphogenetic Protein 7Nudelcsh:MedicineSmad ProteinsFibroblast growth factorBiochemistryNeovascularizationMiceCell Movementlcsh:ScienceBMP7 Angiogenesis TumorTumorMultidisciplinaryCell DeathNeovascularization PathologicMedicine (all)Cell migrationCell biologyEndothelial stem cellSettore MED/26 - NEUROLOGIAVascular endothelial growth factor ADrug CombinationsAdipose TissueAdipose Tissue; Animals; Bone Morphogenetic Protein 7; Cell Death; Cell Line Tumor; Cell Movement; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Fibroblast Growth Factor 2; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Laminin; Male; Mice Nude; Neoplastic Stem Cells; Neovascularization Pathologic; Neovascularization Physiologic; Proteoglycans; Receptor Fibroblast Growth Factor Type 1; Signal Transduction; Smad Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Neoplastic Stem CellsFibroblast Growth Factor 2ProteoglycansCollagenmedicine.symptomReceptorType 1Research ArticleSignal TransductionMice NudeNeovascularization PhysiologicBMP7BiologyCell LineSettore MED/04 - PATOLOGIA GENERALECell Line TumormedicineHuman Umbilical Vein Endothelial CellsAnimalsHumansAgricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Receptor Fibroblast Growth Factor Type 1PhysiologicNeovascularizationCell ProliferationPathologicMatrigelBiochemistry Genetics and Molecular Biology (all)lcsh:REndothelial CellsKinase insert domain receptorVascular Endothelial Growth Factor Receptor-2Xenograft Model Antitumor AssaysAgricultural and Biological Sciences (all)lcsh:QAngiogenesisLamininGlioblastomaPLoS ONE
researchProduct

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity…

2021

Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting. Study design EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2. Results Of the 752 patients enrolled, 745 (99.07…

MaleEaglesAntiVEGF Drugs nAMD clinical practiceVisual AcuitySocial SciencesRetinal NeovascularizationInfographicsGeographical locationsMacular DegenerationMedical ConditionsEndocrinologyRetrospective StudieClinical endpoint80 and overPsychologyAged 80 and overEukaryotaItalyCohortMedicineHumanmedicine.medical_specialtyScienceDrug Administration ScheduleFollow-Up StudieSigns and Symptomsbiology.animalLinear regressionHumansAgedRetrospective StudiesSettore MED/30 - Malattie Apparato VisivoData VisualizationOrganismsBiology and Life Sciencesmedicine.diseaseOphthalmologyMacular DisordersLesionsEyesObservational studyClinical MedicinePeople and placesNeuroscienceVascular Endothelial Growth Factor AVisual acuityTime FactorsEye DiseasesVisionPhysiologyAngiogenesis InhibitorsMedicine and Health SciencesGeriatric OphthalmologyData ManagementMultidisciplinarybiologyQRetinal DegenerationRChartsEuropeAged; Aged 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intravitreal Injections; Italy; Macular Degeneration; Male; Retinal Neovascularization; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual AcuityTreatment OutcomeVertebratesIntravitreal InjectionsRetinal DisordersSensory PerceptionFemalemedicine.symptomAnatomyAngiogenesis InhibitorResearch ArticleEagleComputer and Information SciencesTime FactorBirdsOcular SystemInternal medicineSettore MED/30Growth FactorsmedicineAnimalsEuropean UnionRaptorsEndocrine Physiologybusiness.industryIntravitreal InjectionCognitive PsychologyRetrospective cohort studyMacular degenerationGeriatricsAmniotesCognitive SciencePerceptionbusinessZoologyHeadFollow-Up Studies
researchProduct

Association of neovascular age-related macular degeneration with month and season of birth in Italy

2016

In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF fo…

MaleVascular Endothelial Growth Factor AAginggenetic structuresMonth of birthVEGF receptorsneovascular AMDAngiogenesis InhibitorsAptamersMacular Degeneration0302 clinical medicineSeason of birthReceptors80 and overMedicineRegistriesAged 80 and overNeovascularization PathologicbiologyVascular Endothelial Growth FactorIncidenceIncidence (epidemiology)Aptamers NucleotideBevacizumabTreatment OutcomeItalyanti-VEGFFemaleSeasonsNucleotideNeovascular age-related macular degenerationResearch Papermedicine.drugAnti-VEGF; Month of birth; Neovascular age-related macular degeneration; Neovascular AMD; Season of birth; Aged; Aged 80 and over; Angiogenesis Inhibitors; Aptamers Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization Pathologic; Ranibizumab; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A; Seasons; Aging; Cell BiologySeason of birthBevacizumabRecombinant Fusion ProteinsNeovascular AMDneovascular age-related macular degeneration03 medical and health sciencesRanibizumabAge relatedHumansNeovascularizationAgedPathologicseason of birthbusiness.industrymonth of birthAnti-VEGFCell BiologyMacular degenerationmedicine.diseaseeye diseasesanti-VEGF; month of birth; neovascular AMD; neovascular age-related macular degeneration; season of birthReceptors Vascular Endothelial Growth Factor030221 ophthalmology & optometrybiology.proteinsense organsRanibizumabbusinessMonth of birth030217 neurology & neurosurgeryDemographyAging
researchProduct

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Monoclonal antibodies in gastrointestinal cancers

2013

Introduction: Among gastrointestinal cancers, colorectal and gastric neoplasms are the most frequent. The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those malignancies. Areas covered: This review highlights the main biological processes implicated in gastrointestinal cancer development and progression, such as angiogenesis and epidermal growth factor receptor (EGFR) signaling pathway. On these bases, anti-EGFR and anti-vascular endothelial growth factor (VEGF) monoclonal antibodies in colorectal and gastric cancer are discussed. Data about further monoclonal antibodies in development are also reported. Expert opinion: The use of monoclo…

OncologyVascular Endothelial Growth Factor AColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryPredictive Value of TestAntineoplastic AgentVascular Endothelial Growth Factor A; Animals; Antineoplastic Agents; Receptor Epidermal Growth Factor; Humans; Molecular Targeted Therapy; Predictive Value of Tests; Patient Selection; Antibodies Monoclonal; Genetic Testing; Individualized Medicine; Gastrointestinal Neoplasms; Tumor Markers Biological; Signal TransductionGastricDrug DiscoveryMonoclonalEpidermal growth factor receptorMolecular Targeted TherapyPrecision MedicineTumor MarkersColorectalCancerGastrointestinal NeoplasmsbiologyAntibody; Cancer; Colorectal; Gastric; Monoclonal; Animals; Antibodies Monoclonal; Antineoplastic Agents; Gastrointestinal Neoplasms; Genetic Testing; Humans; Individualized Medicine; Molecular Targeted Therapy; Patient Selection; Predictive Value of Tests; Receptor Epidermal Growth Factor; Signal Transduction; Tumor Markers Biological; Vascular Endothelial Growth Factor A; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalIndividualized MedicineErbB ReceptorsTumor Markers BiologicalGastrointestinal NeoplasmMonoclonalGastric NeoplasmHumanReceptorSignal Transductionmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsMonoclonal antibodyAntibodiesPredictive Value of TestsInternal medicinemedicineBiomarkers TumorAnimalsHumansGastrointestinal cancerGenetic TestingAntibodyPharmacologyEpidermal Growth Factorbusiness.industryAnimalDrug Discovery3003 Pharmaceutical SciencePatient SelectionCancermedicine.diseaseBiologicalbiology.proteinReceptor Epidermal Growth Factorbusiness
researchProduct